Please provide your email address to receive an email when new articles are posted on . A novel SK ion channel inhibitor more often converted atrial fibrillation to sinus rhythm compared with placebo.

Proteins involved in physiological processes of the heart have been a target of research for AFib for some time. Until recently, most research suggested that treating AFib through inhibition of ...

Researchers identified a lipid that is involved in regulating cardiac ion channels, providing insights into possible mechanisms of cardiac arrhythmias in heart failure and a potential pathway for ...

Acesion Pharma ApS has announced promising data from preclinical studies with AP-31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers Phase 2 trial will assess ...